Even with the development and FDA approval in recent years of the first rapid-acting antidepressant medicines—to which more than 90 BBRF grants have contributed—the search for novel depression…
Read More
On August 4th, the U.S. Food and Drug Administration (FDA) approved zuranolone, the first oral medication designed to treat postpartum depression (PPD) in adults. The drug, which is rapid-acting, was…
Read More
